<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720535</url>
  </required_header>
  <id_info>
    <org_study_id>CLN0011</org_study_id>
    <nct_id>NCT03720535</nct_id>
  </id_info>
  <brief_title>A Study to Collect Information Related to the Cordio System</brief_title>
  <official_title>An Observational Study to Collect Information Related to the Clinical Significance and Performance of the Cordio System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordio Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordio Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, observational, non-interventional, prospective, Single-arm, open
      study for database establishment for R&amp;D purposes. R&amp;D data will be analyzed retrospectively
      in order to validate algorithm efficacy.

      The study will be conducted in the following settings- hospital and at home.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>R&amp;D Database &amp; Efficiency- voice signal analysis</measure>
    <time_frame>throughout study, 1-2 years per patient</time_frame>
    <description>Building R&amp;D recording database and retrospectively Cordio System needs to reach correlation between the system generated alerts (using voice signal analysis- Hz) to HF deterioration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usability- SUS</measure>
    <time_frame>throughout study, 1-2 years per patient</time_frame>
    <description>SUS scale in order to assess the app usability. SUS scale is in the range of 0-100 when higher results are better.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety- Adverse Events</measure>
    <time_frame>Throughout Study, 1-2 years per patient</time_frame>
    <description>Demonstration of the safe use of the device by means of analysis of overall incidence and severity of device related adverse events.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HF patients</arm_group_label>
    <description>HF patients will use the Cordio Medical app to record</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cordio Medical</intervention_name>
    <description>App used for recording, no medical intervention in the patient regular care</description>
    <arm_group_label>HF patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NYHA 2-3 who are being followed-up at the hospital. All patients must meet
        eligibility criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic Heart Failure Patient.

          -  Patient with reduced or preserved EF CHF.

          -  Patient with more than 3 months HF disease duration.

          -  Patient who passes the &quot;App usage&quot; screening questionnaire (see Appendix B)

          -  The patient is willing to participate as evidenced by signing the written informed
             consent.

          -  Male or non pregnant female patient

        Exclusion Criteria:

          -  Subject who, in the Investigator's opinion, unable to comply with the daily use of the
             App due to mental disorders (e.g., depression, dementia).

          -  Patient who has had a major cardiovascular event (e.g., myocardial infraction, stroke)
             within 3 months prior to screening visit.

          -  Subject with known coagulation disorders.

          -  Subject with evidence of active Infection.

          -  Patient with severe alcohol or drug use.

          -  Psychological instability, inappropriate attitude or motivation.

          -  Patient with life threatening debilitating disease other than cardiac.

          -  Subject currently enrolled in another investigational device or drug trial that has
             not completed the primary endpoint or that clinically interferes with the current
             study endpoints.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tuvia Ben Gal, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orit Ronen, MSc</last_name>
    <phone>972-3-5467163</phone>
    <phone_ext>205</phone_ext>
    <email>orit@cordio-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuvia Ben Gal, Dr.</last_name>
      <phone>03-9377337</phone>
      <email>bengaltu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

